• FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

    Источник: Nasdaq GlobeNewswire / 28 июл 2025 04:00:00   America/Los_Angeles

    N/A
Опубликовать